Colorectal Cancer | Specialty

Dr. Eng Discusses Results of the PRODIGE 7 Trial

July 23rd 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses why the negative results of the PRODIGE 7 trial are beneficial moving forward.

Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab

July 20th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.

Dr. Ulahannan on the VALENTINO Trial in Advanced CRC

July 20th 2018

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the VALENTINO trial in advanced colorectal cancer (CRC).

West Coast Study Rates Cancer Centers by Cost and Quality

July 17th 2018

In a groundbreaking study of costs and quality of cancer care among cancer clinics in the state of Washington, investigators found wide disparity in end-of-life care, suggesting that improvements in cost and quality could be attained if treatment centers share information on what works and endeavor to improve.

Dr. Yezefski Compares Costs and Outcomes of Chemotherapy in the US and Canada

July 16th 2018

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, compares the costs and outcomes of chemotherapy in the United States and Canada for patients with colorectal cancer.

Dr. Choti on Updates in Neoadjuvant and Adjuvant Therapy for CRC

July 13th 2018

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses updates in neoadjuvant and adjuvant therapy for patients with colorectal cancer.

Dr. Eng on the FDA Approval of Nivolumab Plus Ipilimumab in CRC

July 11th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer

July 11th 2018

The FDA has approved the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Dr. Bekaii-Saab on the ReDOS Study in Metastatic Colorectal Cancer

June 27th 2018

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the ReDOS study of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Dr. Schwark on Microsatellite Instability and Lynch Syndrome

June 27th 2018

Alicia Latham Schwark, MD, medical genetics fellow, Memorial Sloan Kettering Cancer Center, discusses a study exploring microsatellite instability (MSI) and how it relates to Lynch syndrome across all tumor types. The findings were presented at the 2018 ASCO Annual Meeting.

Grothey Grapples With Treatment Options in mCRC

June 26th 2018

Axel Grothey, MD, discusses sidedness and first- and second-line treatments for patients with metastatic colorectal cancer.

Trifluridine/Tipiracil Plus Bevacizumab Improves Survival in Patients With mCRC

June 26th 2018

Patients with metastatic colorectal cancer who are not eligible for chemotherapy or surgical resection may have a new first-line treatment option.

Dr. Kopetz on the Importance of Molecular Testing in CRC

June 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer.

Regorafenib Dose-Escalation Superior to Standard Dosing in mCRC

June 22nd 2018

Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.

TAS-102 Benefit Consistent in Real-World Study for mCRC

June 22nd 2018

TAS-102 (trifluridine/tipiracil; Lonsurf) continued to show consistent benefits and safety in a real-world treatment setting for patients with refractory metastatic colorectal cancer.

Atezolizumab Combo Not Superior to Regorafenib for mCRC

June 22nd 2018

Atezolizumab alone or in combination with cobimetinib failed to show superior overall survival compared with regorafenib for patients with chemorefractory metastatic colorectal cancer.

Bekaii-Saab Highlights Emerging Treatments for Patients With mCRC

June 22nd 2018

Tanios Bekaii-Saab, MD, outlines clinical trials that have defined the current landscape of metastatic colorectal cancer and what research is underway.

Advanced CRC: Pushing the Treatment Paradigm Forward

June 20th 2018

Discerning HIPEC

June 20th 2018

Advanced CRC: Liquid Biopsies and the CRICKET Study

June 20th 2018